BioSpace News Archive

Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it will release its financial results for the third quarter ended September 30, 2022, on Monday, November 14, 2022, after the market close.

Asklepios BioPharmaceutical, Inc. announced that R. Jude Samulski, Ph.D., AskBio President, Co-Founder and Chief Scientific Officer, received the inaugural European Society of Gene and Cell Therapy Founders Award in Edinburgh, Scotland, during the recent ESGCT 29th Congress.

Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamab.

The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Abbott’s FreeStyle Libre® continuous glucose monitoring technology as the “Best Medical Technology” of the last 50 years during its Prix Galien Golden Jubilee Awards ceremony on Oct. 27 in New York City.

Nuevocor announced today that it will present new preclinical data on its adeno-associated virus (AAV) gene therapy for LMNA dilated cardiomyopathy at the American Heart Association (AHA) Scientific Sessions meeting on 5 – 7 November, 2022.

Cybrexa Therapeutics today presented findings as a plenary oral presentation at the annual EORTC-NCI-AACR (ENA) Symposium on molecular targets and cancer therapeutics.

Tavanta Therapeutics, a clinical-stage specialty pharmaceutical company, today announced that it will present preclinical data on TAVT-135, a cell-penetrating peptide conjugate, at the Cystic Fibrosis Foundation Conference.

ThermoGenesis Holdings, Inc. announced the closing of its previously announced public offering of 11,783,572 shares of its common stock, $0.001 par value, 2,892,858 pre-funded warrants to purchase Common Shares, and warrants to purchase up to an aggregate 14,676,430 Common Shares at an offering price to the public of $0.14 per share and associated warrant.

SomnoMed Limited, a leading company in the provision of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea, is pleased to provide its quarterly activities report for the period ended 30 September 2022.

Senti Biosciences, Inc. announced that on October 27, 2022, the compensation committee of Senti Bio’s board of directors granted to 9 new employees stock options to purchase an aggregate of 200,200 shares of the Company’s common stock with a per share exercise price of $2.39.